Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|March 7, 2025

Chapter 2: Neurocircuitry & Neuroplasticity in the Biology of Depression: Rewiring the Brain

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

The Postmodern Worldview and Contemporary Psychiatry

DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD

Choosing Sexual Function-Sparing Medications

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

New Phase 3 Data on Oveporexton for Narcolepsy Type 1